CCBR-SYNARC and BioClinica, Inc. have announced an agreement to merge their companies to create a leading global provider of specialized outsourced clinical services. The merger is expected to complete in the first quarter of 2014. Financial terms were not disclosed.
The combined company will offer a portfolio of services uniquely tailored to conducting and managing global clinical trials on behalf of the world’s premier pharmaceutical and biotechnology companies. Jeffrey McMullen, vice chairman of inVentiv Health, Inc., will serve as chairman of the combined company. Mark Weinstein, president & CEO of BioClinica, will serve as CEO.
This merger comes at a time when demand for outsourced pharmaceutical services is projected to grow more than 5% per year over the next five years.